Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet's syndrome patients with gastrointestinal involvement.

Esatoglu SN, Hatemi I, Ozguler Y, Hatemi G, Uzun H, Celik AF, Yazici H.

Clin Exp Rheumatol. 2018 Nov-Dec;36(6 Suppl 115):90-96. Epub 2018 Dec 13.

2.

Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations.

Ozguler Y, Leccese P, Christensen R, Esatoglu SN, Bang D, Bodaghi B, Çelik AF, Fortune F, Gaudric J, Gul A, Kötter I, Mahr A, Moots RJ, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H, Hatemi G.

Rheumatology (Oxford). 2018 Dec 1;57(12):2200-2212. doi: 10.1093/rheumatology/key242.

PMID:
30107448
3.

Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome.

Leccese P, Ozguler Y, Christensen R, Esatoglu SN, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gül A, Kötter I, Mahr A, Moots RJ, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H, Hatemi G.

Semin Arthritis Rheum. 2019 Feb;48(4):752-762. doi: 10.1016/j.semarthrit.2018.05.008. Epub 2018 May 19.

PMID:
29954598
4.

Assessing the possible association of anti-TNF use with new malignancies: A neglected methodological consideration.

Ozguler Y, Yazici Y, Hatemi G, Tascilar K, Yazici H.

Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):894-901. doi: 10.1002/pds.4579. Epub 2018 Jun 19. No abstract available.

PMID:
29920843
5.

2018 update of the EULAR recommendations for the management of Behçet's syndrome.

Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kötter I, Leccese P, Mahr A, Moots R, Ozguler Y, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H.

Ann Rheum Dis. 2018 Jun;77(6):808-818. doi: 10.1136/annrheumdis-2018-213225. Epub 2018 Apr 6.

PMID:
29625968
6.

Exacerbation of Behçet's syndrome and familial Mediterranean fever with menstruation.

Guzelant G, Ozguler Y, Esatoglu SN, Karatemiz G, Ozdogan H, Yurdakul S, Yazici H, Seyahi E.

Clin Exp Rheumatol. 2017 Nov-Dec;35 Suppl 108(6):95-99. Epub 2017 Oct 24.

7.

Myelopathy in Behçet's disease: The Bagel Sign.

Uygunoglu U, Zeydan B, Ozguler Y, Ugurlu S, Seyahi E, Kocer N, Islak C, Kantarci K, Saip S, Siva A, Kantarci OH.

Ann Neurol. 2017 Aug;82(2):288-298. doi: 10.1002/ana.25004. Epub 2017 Aug 10.

PMID:
28749553
8.

Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016.

Hatemi G, Meara A, Ozguler Y, Direskeneli H, Mahr A, Easley E, Gurcan M, Davis T, Gul A, Yazici Y, Zottenberg K, Esatoglu SN, Erer B, Kamali S, Yazici H, Cronholm PF, Merkel PA.

J Rheumatol. 2017 Nov;44(11):1750-1753. doi: 10.3899/jrheum.161352. Epub 2017 Apr 1.

PMID:
28365574
9.

Inadequate reporting of enrolled patient and study site characteristics, and inter-study site differences in randomized controlled trials: A systematic review in six leading medicine journals.

Yurdakul S, Ayan G, Ozguler Y, Hatemi G, Ugurlu S, Seyahi E, Yazici H.

Eur J Intern Med. 2017 Jan;37:e34-e36. doi: 10.1016/j.ejim.2016.09.019. Epub 2016 Oct 5. Review. No abstract available.

PMID:
27720299
10.

Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.

Ozguler Y, Hatemi G, Ugurlu S, Seyahi E, Melikoglu M, Borekci S, Atahan E, Ongen G, Hamuryudan V.

Rheumatol Int. 2016 Dec;36(12):1719-1725. Epub 2016 Oct 3.

PMID:
27699578
13.

Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence.

Kisacik B, Pamuk ON, Onat AM, Erer SB, Hatemi G, Ozguler Y, Pehlivan Y, Kilic L, Ertenli I, Can M, Direskeneli H, Keser G, Oksel F, Dalkilic E, Yilmaz S, Pay S, Balkarli A, Cobankara V, Cetin GY, Sayarlioglu M, Cefle A, Yazici A, Avci AB, Terzioglu E, Ozbek S, Akar S, Gul A.

J Rheumatol. 2016 Mar;43(3):524-9. doi: 10.3899/jrheum.150177. Epub 2016 Jan 15.

PMID:
26773107
14.

Management of Behçet's syndrome.

Ozguler Y, Hatemi G.

Curr Opin Rheumatol. 2016 Jan;28(1):45-50. doi: 10.1097/BOR.0000000000000231. Review.

PMID:
26555450
15.

Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014.

Hatemi G, Ozguler Y, Direskeneli H, Mahr A, Gul A, Levi V, Aydin SZ, Mumcu G, Sertel-Berk O, Stevens RM, Yazici H, Merkel PA.

J Rheumatol. 2015 Dec;42(12):2436-41. doi: 10.3899/jrheum.141147. Epub 2015 Sep 15. Review.

16.

Pulmonary artery involvement in Behçet׳s syndrome: Effects of anti-Tnf treatment.

Hamuryudan V, Seyahi E, Ugurlu S, Melikoglu M, Hatemi G, Ozguler Y, Akman C, Tuzun H, Yurdakul S, Yazici H.

Semin Arthritis Rheum. 2015 Dec;45(3):369-73. doi: 10.1016/j.semarthrit.2015.06.008. Epub 2015 Jun 18.

PMID:
26190564
17.

Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-α treatment.

Borekci S, Atahan E, Demir Yilmaz D, Mazıcan N, Duman B, Ozguler Y, Musellim B, Hamuryudan V, Ongen G.

Respiration. 2015;90(3):191-8. doi: 10.1159/000434684. Epub 2015 Jun 30.

18.

Management of Behçet's syndrome.

Ozguler Y, Hatemi G, Yazici H.

Curr Opin Rheumatol. 2014 May;26(3):285-91. doi: 10.1097/BOR.0000000000000050. Review.

PMID:
24614278

Supplemental Content

Loading ...
Support Center